Story

Tempus AI Stock Climbs on Analyst Upgrades Following Personalis Acquisition Filing

ENTHMSVIIDZHZH-TWJAKOHI
Sep 1, 20261 min read
Tempus AI Stock Climbs on Analyst Upgrades Following Personalis Acquisition Filing
Text size
Background

Tempus AI (NASDAQ: TEM) shares rose 2.7% in pre-open trading after two Wall Street firms issued bullish notes on the company, citing new details surrounding its pending acquisition of Personalis.

Analyst Actions Drive Gains

Piper Sandler upgraded Tempus AI shares to Overweight from Neutral and raised its price target to $76 from a previous $56. The firm's analysts pointed to three key growth catalysts for the company:

  • The strategic value of Personalis's differentiated tumor-informed Minimal Residual Disease (MRD) platform.
  • A positive data readout from the INTerpath-001 study.
  • The potential for FDA approval of Tempus's tumor-only xT genomic test.

Adding to the positive sentiment, Canaccord Genuity reiterated its Buy rating and $80 price target on the stock. The firm's confidence was reinforced by Tempus AI’s S-4 filing on August 31 for the Personalis deal.

Sample IUX Markets – In-articleAd

Strategic Context and Market Performance

The regulatory filing detailed a competitive sale process for Personalis that began in May 2024 and involved multiple strategic bidders. According to the filing, one direct competitor's proposal was flagged for significant antitrust concerns, a detail that Canaccord Genuity believes underscores the strategic value of the asset Tempus AI secured.

The company-specific optimism allowed Tempus AI to buck a broader market downturn, with major indices like the S&P 500 and Nasdaq trading lower in the pre-market session. The analyst actions build upon a solid fundamental picture, following a second-quarter report where Tempus AI achieved profitability and raised its full-year 2026 revenue guidance to approximately $1.6 billion.

Read next

More on Stocks
Back to latest news

LATEST